Pfizer's Beqvez taking on Hemgenix with FDA nod in hemophili

Pfizer Inc.’s Beqvez (fidanacogene elaparvovec) won FDA approval for use in adults with hemophilia B, making it the second adeno-associated viral (AAV) vector-based gene therapy available for patients in the U.S., following the late 2022 approval of CSL Behring’s Hemgenix (etranacogene dezaparvovec).

Related Keywords

Behring Hemgenix , Pfizer Inc , , Beqvez , Hemophilia B , Adeno Associated Viral Vectors , Maav , Regulatory , Us , Hematologic , Gene Therapy , Bioworld , Drugs , Fda ,